Casirivimab/imdevimab vs placebo
Adverse events: all grades · SARS‐CoV‐2 uninfected people without defined exposure, or with potential exposure to SARS‐CoV‐2
Casirivimab/imdevimab leads to lower adverse events: all grade until data cut‐offb compared with placebo (high certainty).
1 finding from 1 review
- SARS‐CoV‐2‐neutralising monoclonal antibodies to prevent COVID‐19 2022 · Cochrane Headline outcomes onlyRR 0.7 [0.61, 0.8]1 study · 2617 participantsHigh